P-0189 - Lack of association between SMAD7 gene polymorphism and risk of colorectal cancer in an Iranian population

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Colon Cancer
Rectal Cancer
Pathology/Molecular Biology
Translational Research
Presenter Zahra Akbari
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors Z. Akbari1, N. Safari-Alighiarloo2, M. Vahedi3, M. Montazer Haghighi3
  • 1Basic And Molecular Epidemiology Of Gastrointestinal Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran/IR
  • 2Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran/IR
  • 3Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran/IR

Abstract

Introduction

SMAD7 which is located at 18q21 plays inhibitory roles in the transforming growth factor beta (TGF-b) signaling pathway which is involved in many cellular processes and has an important role in cancer development and progression. This protein is a prominent antagonist of TGF-b signaling pathway which has a known role in tumorigenesis. It has suggested that the SMAD7 gene has association with colorectal cancer risk. Potential polymorphisms in SMAD7 may alter cancer risk. Therefore, we hypothesized that single-nucleotide polymorphisms in SMAD7 gene were associated with risk and clinicopathologic feature of colorectal cancer. The aim of this study was.

Methods

This case-control study included 210 subjects (105 patients with sporadic colorectal cancer and 105 healthy controls). Determination of genotypes were performed by TaqMan assay using predesigned TaqMan probes (C-26177715-20; Applied Biosystems, Foster City, CA) via an ABI 7500 Real Time PCR System (Applied Biosystems) with DNA from peripheral blood. Logistic regression analyses were performed to calculate odds ratios (ORs) as a measure of association of genotypes with risk of colorectal cancer and clinicopathological features such as tumor grade, location and TNM stage.

Results

There was no significant association between rs2337107 genotypes and the risk of colorectal cancer, even after adjustment for sex, age and smoking status. There wasn't any difference in the genotypic and allelic frequencies between case and control groups (OR [95% CI] = 1.601 [0.719-1.563], P = 0.767). Also there was no significant association between this polymorphism and clinicopathological features (P value > 0.05).

Conclusion

Although SMAD7 gene located at a risk locus (18q21) for CRC, our results did not show any significant association between SMAD7 gene polymorphism (rs2337107) and colorectal cancer risk and clinicopathological features in an Iranian population. There are some studies which consistent with our results revealed that there was no significant association between SMAD7 gene polymorphism (rs2337107) and CRC risk. Our results suggest a large-scale case-control study to validate this SNP as a non-contributor to the risk of colorectal cancer in an Iranian population. Key words: Colorectal Cancer (CRC), SMAD7 gene, Single Nucleotide Polymorphism (SNP).